Combo Immunotherapy in NSCLC: Not These Two Drugs ...Middle East

News by : (Medscape) -
Pembrolizumab monotherapy remains a standard of care, after trial results show that adding ipilimumab conveys no benefits but incurs greater toxicity. Medscape Medical News

Hence then, the article about combo immunotherapy in nsclc not these two drugs was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Combo Immunotherapy in NSCLC: Not These Two Drugs )

Last updated :

Also on site :

Most Viewed News
جديد الاخبار